• HOME
• About CHIYODA

  • Message from Management

  • Corporate Profile

  • Corporate Profile
  • Major Domestic Subsidiaries & Affiliated Companies
  • Major Overseas Subsidiaries & Affiliated Companies

  • History

  • Philosophy/Vision/Policies

  • Philosophy / Vision / Policies
  • CORPORATE SQE POLICY
  • Corporate Information Security Policy
  • Code of Conduct of the Chiyoda Group
  • Privacy Policy
  • CSR vision
  • Chiyoda Group Compliance Manual

  • Organization

  • Corporate Governance

  • Board of Directors

  • Directors & Officers
  • Management Team（Representative Directors）

  • Access to CHIYODA

  • Yokohama Head Office
  • Koyasu Office & Research Park
  • Kawasaki Office
  • Tokyo Office
• Service

  • Planning Phase

  • Master Planning
  • Feasibility Studies (FS)
  • Licensing
  • Process Development Support

  • EPC Phase

  • FEED (Front End Engineering Design)
  • Engineering
  • Procurement
  • Construction
  • Commissioning

  • Operation and Maintenance Phase

  • Process Improvements
  • Utility System Improvements
  • Improvements in Equipment Reliability
  • Environmental Improvements
  • O&M Consulting Service
• Technology
  • LNG
  • Upstream / Gas Processing
  • Refinery
  • Synthetic Gas / GTL
  • Petrochemical / Chemical
  • Nuclear Energy-related Matters, etc.
  • Green Energy related
  • Pharmaceutical
  • Environmental
  • Technologies for the Future
  • Advanced Engineering Technology
• Project

  • Location

  • Far East Asia
  • Asia & Oceania
  • Middle East
  • Africa
  • Europe
  • the Americas

  • Scope of Work

  • LNG/Gas Processing
  • LNG/LPG Terminal
  • Petroleum Refineries
  • Oil Terminal
  • Petrochemical & Chemical
  • Flue Gas Desulfurization
  • Pharmaceutical
  • Green Energy

  • Year of Completion

  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
• News
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • Regarding the earthquake
• Investor Relations

  • Management Srrategy

  • Medium-Term Management Plan
  • Risk Factors

  • IR library

  • Report to TSE / Press Release
  • Annual Report
  • Fact Book
  • Notice of the General Meeting of Shareholders

  • IR Calender

  • Stock & Share Information

  • Major Shareholders
  • Dividend Policy
  • Articles of incorporation

  • Analyst Coverage

• CSR

  • A Message from the President

  • Commitment to CSR

  • CSR Policy
  • Chiyoda Group CSR Vision

  • Corporate Governance

  • CSR Report

  • A Reliable Company (Vision 1)

  • Quality Management Initiatives
  • Working with Business Partners

  • Environmental Initiatives (Vision 2)

  • Environmental Management
  • Environmental Conservation Activities ・ Environmental Data
  • Low Carbon Society

  • Social Contributions through Business Activities (Vision 3)

  • Community
  • Human Resources
  • Fundraising ・ Donations

  • Respect for Human Rights (Vision 4)

  • Employee Skill Development and Work Environment
  • Occupational Health and Safety

  • Commitment to Fairness (Vision 5)

  • Code of Conduct of the Chiyoda Group
  • Compliance
  • Information Security Management and Export Control

• Japanese
• English

Pharmacological Research Building Project

Location	Japan	Year of Completion	2005
Scope of Work	Pharmaceutical	Plant	Bio, Clinical
Capacity	Construction Area:2,750m2 Total Area:10,800m2	Scope	E.P.C.V
Client	Mitsubishi Tanabe Pharma Factory Ltd.	Location	Kanagawa

The construction of a highly versatile, easy to use, and safe building was sought by sealing off each section and employing a modular structure

Maintenance is simplified, since all equipment can be maintained without personnel needing to enter into the clean areas

Running costs are reduced by using a function that varies the ventilation rate for the air conditioning, inverter-controlled freezers, lighting control using human sensors, and insulated outside walls

Good communication is ensured among employees through the arrangement of office and community spaces taking the advantage of the bright atrium